Dexcom announced the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes will ...

Dexcom’s “Smart Basal” has received FDA clearance for people with type 2 diabetes using long-acting insulin. The feature will ...

NEW YORK, NY / ACCESS Newswire / November 20, 2025 / If you suffered a loss on your DexCom, Inc. (NASDAQ:DXCM) investment and want to learn about a potential recovery under the federal securities laws ...

DexCom receives FDA clearance for DexCom Smart Basal titration software module, which optimizes basal insulin dose in type 2 ...

Dexcom (NSDQ:DXCM) announced today that it plans to launch its G7 15 Day continuous glucose monitor (CGM) in the U.S. next ...

Dexcom Inc. received U.S. FDA clearance for its Smart Basal CGM-integrated basal insulin dosing optimizer. Designed for adults with type 2 diabetes using glargine U-100 long-acting insulin therapy, ...

In honor of National Diabetes Awareness Month, DAV (Disabled American Veterans) announced today a new strategic partnership ...

Dexcom (NSDQ:DXCM) announced today that the FDA cleared its Smart Basal CGM-integrated basal insulin dosing optimizer.

(NASDAQ: DXCM), the global leader in glucose biosensing, announced today the FDA has cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer designed for adults ...

DexCom's stock narrative has shifted as analysts lower their fair value estimate from $98.40 to $84.96, marking a significant downward revision in the price target. This adjustment is primarily driven ...

According to Diabète Québec, type 2 diabetes is the most common form, affecting nearly 90% of those living with diabetes, and many eventually require insulin when lifestyle changes and oral ...

[BRIEFING.COM] The S&P 500 (+0.33%) is in second place on Friday afternoon, up about 23 points. Meanwhile, Dexcom (DXCM 59.49, -8.71, -12.77%) is today's worst laggard after posting a steep Q3 revenue ...